Abstract
FTY720 is a recently approved first line therapy for relapsing forms of multiple sclerosis. In this context, FTY720 is a pro-drug, with its anti-multiple sclerosis, immunosuppressive effects largely elicited following its phosphorylation by sphingosine kinase 2 and subsequent modulation of G protein-coupled sphingosine 1-phosphate (S1P) receptor 1 that induces lymphopenia by altering lymphocyte trafficking. A number of other biological effects of FTY720 have, however, been described, including considerable evidence that this drug also has anti-cancer properties. These other effects of FTY720 are independent of S1P receptors, and appear facilitated by modulation of a range of other recently described protein targets by nonphosphorylated FTY720. Here, we review the direct targets of FTY720 that contribute to its anti-cancer properties. We also discuss other recently described protein effectors that, in combination with S1P receptors, appear to contribute to its immunosuppressive effects.
Keywords: Apoptosis, cancer, FTY720, fingolimod, lymphopenia, lysophospholipid, sphingosine, sphingosine 1-phosphate, therapeutic drug, Gilenya™, myriocin, immunosuppressive activity, immuno-suppressants, toxicity, multiple sclerosis
Current Molecular Medicine
Title:Molecular Targets of FTY720 (Fingolimod)
Volume: 12 Issue: 10
Author(s): M.R. Pitman, J.M. Woodcock, A.F. Lopez and S.M. Pitson
Affiliation:
Keywords: Apoptosis, cancer, FTY720, fingolimod, lymphopenia, lysophospholipid, sphingosine, sphingosine 1-phosphate, therapeutic drug, Gilenya™, myriocin, immunosuppressive activity, immuno-suppressants, toxicity, multiple sclerosis
Abstract: FTY720 is a recently approved first line therapy for relapsing forms of multiple sclerosis. In this context, FTY720 is a pro-drug, with its anti-multiple sclerosis, immunosuppressive effects largely elicited following its phosphorylation by sphingosine kinase 2 and subsequent modulation of G protein-coupled sphingosine 1-phosphate (S1P) receptor 1 that induces lymphopenia by altering lymphocyte trafficking. A number of other biological effects of FTY720 have, however, been described, including considerable evidence that this drug also has anti-cancer properties. These other effects of FTY720 are independent of S1P receptors, and appear facilitated by modulation of a range of other recently described protein targets by nonphosphorylated FTY720. Here, we review the direct targets of FTY720 that contribute to its anti-cancer properties. We also discuss other recently described protein effectors that, in combination with S1P receptors, appear to contribute to its immunosuppressive effects.
Export Options
About this article
Cite this article as:
Pitman M.R., Woodcock J.M., Lopez A.F. and Pitson S.M., Molecular Targets of FTY720 (Fingolimod), Current Molecular Medicine 2012; 12 (10) . https://dx.doi.org/10.2174/156652412803833599
DOI https://dx.doi.org/10.2174/156652412803833599 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers
Medicinal Chemistry Bioactivity of Chitosan and Its Derivatives
Current Organic Chemistry Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety The Potential of Natural Products as Effective Treatments for Allergic Inflammation: Implications for Allergic Rhinitis
Current Topics in Medicinal Chemistry Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Synthesis and Biological Evaluation of 2-, 3-, and 4-Acylaminocinnamyl-Nhydroxyamides as Novel Synthetic HDAC Inhibitors
Medicinal Chemistry Pharmacogenomics of Xenobiotic Metabolizing Enzymes in South American Populations
Current Pharmacogenomics Plant-Derived Products as Antibacterial and Antifungal Agents in Human Health Care
Current Medicinal Chemistry Extracellular Matrix Scaffolds for Tissue Engineering and Regenerative Medicine
Current Stem Cell Research & Therapy Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Antitumor Evaluation of Thiophene Analogs of Kigelinone
Letters in Organic Chemistry Molecular Architecture of Tumor Suppressor p53
Current Topics in Medicinal Chemistry Bioactive Polyphenols from Healthy Diets and Forest Biomass
Current Nutrition & Food Science Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Expression Profiles and Bioinformatics Analysis of Full-length circRNA Isoforms in Gliomas
Current Bioinformatics The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine Insights into Cellular Uptake of Nanoparticles
Current Drug Delivery Serum miRNAs Signature Plays an Important Role in Keloid Disease
Current Molecular Medicine Human Aurora / Ipl1p Related Kinases
Current Genomics Extracellular ATP and Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders